TY - JOUR
T1 - Cutting edge
T2 - Activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype
AU - Singh, Nagendra
AU - Hong, Seokmann
AU - Scherer, David C.
AU - Serizawa, Isao
AU - Burdin, Nicolas
AU - Kronenberg, Mitchell
AU - Koezuka, Yasuhiko
AU - Van Kaer, Luc
PY - 1999/9/1
Y1 - 1999/9/1
N2 - NK T cells recognize glycolipid Ags such as α-galactosylceramide (α- GalCer) presented by the MHC class I-like molecule CD1d. In this paper we have studied the in vivo effects of α-GalCer on the generation of adaptive immune responses. Treatment of mice with α-GalCer resulted in rapid activation of NK T cells and production of the cytokines IL-4 and IFN-γ. However, after this initial stimulation, NK T cells became polarized for the production of IL-4. Further, as soon as 6 days after α-GalCer injection, a marked increase in serum IgE levels was observed. Administration of α-GalCer at the time of priming of mice with protein Ag resulted in the generation of Ag-specific Th2 cells and a profound increase in the production of IgE. Collectively, these findings indicate that α-GalCer may be useful for modulating immune responses toward a Th2 phenotype during prophylaxis and therapy.
AB - NK T cells recognize glycolipid Ags such as α-galactosylceramide (α- GalCer) presented by the MHC class I-like molecule CD1d. In this paper we have studied the in vivo effects of α-GalCer on the generation of adaptive immune responses. Treatment of mice with α-GalCer resulted in rapid activation of NK T cells and production of the cytokines IL-4 and IFN-γ. However, after this initial stimulation, NK T cells became polarized for the production of IL-4. Further, as soon as 6 days after α-GalCer injection, a marked increase in serum IgE levels was observed. Administration of α-GalCer at the time of priming of mice with protein Ag resulted in the generation of Ag-specific Th2 cells and a profound increase in the production of IgE. Collectively, these findings indicate that α-GalCer may be useful for modulating immune responses toward a Th2 phenotype during prophylaxis and therapy.
UR - http://www.scopus.com/inward/record.url?scp=0033198183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033198183&partnerID=8YFLogxK
M3 - Article
C2 - 10452969
AN - SCOPUS:0033198183
SN - 0022-1767
VL - 163
SP - 2373
EP - 2377
JO - Journal of Immunology
JF - Journal of Immunology
IS - 5
ER -